healthevidencedigest https://validator.w3.org/feed/docs/rss2.html AML in Older Adults Has Been Treated With IV Infusions for Years. The FDA Just Approved the First All-Oral Alternative. The Combination Acne Gel Dermatologists Have Prescribed for 15 Years Is Now Available Without a Prescription. Datroway Is Now FDA-Approved for Immunotherapy-Ineligible Metastatic TNBC. Here Is What the TROPION-Breast02 Data Shows and What the Accelerated Approval Means. AI-Supported Mammography Just Got Its Strongest Evidence Yet. Here Is What the Landmark MASAI Trial Found. Linzess Is Now Approved for Children as Young as Two. Here Is What Parents and Pediatric Clinicians Need to Know About the First Prescription Therapy for Pediatric Functional Constipation in This Age Group. The First Biosimilars to Simponi and Simponi Aria Just Got FDA Approval. Here Is What Immgolis and Immgolis Intri Are, What They Treat, and Why You Cannot Buy Them Yet. A Child’s Legs Grow Stiffer Every Year. For Decades, Nothing Could Stop It. The FDA Just Approved the First Drug That Addresses Why. The Only Drug Ever Approved in the United States for Hepatitis Delta Is Now Available. Here Is What Hepcludex Is and What the MYR301 Trial Data Shows. A Blood Test After Bladder Cancer Surgery Can Now Guide Whether You Need Immunotherapy. The FDA Just Approved the First-Ever ctDNA-Guided Cancer Treatment. Another Interchangeable Basal Insulin Just Received FDA Approval. Here Is What Langlara Is, Who It Is For, and What the Access Conversation Still Needs. 365 Injections a Year, or 52. Awiqli Is the First Once-Weekly Basal Insulin and the Science Behind It Is More Interesting Than the Dosing Schedule. Foundayo™ Is the First GLP-1 Pill You Can Take Any Time, With Anything. Here’s What the Trial Data Shows and What the FDA Is Still Waiting to Find Out. Prolia Costs $2,500 a Dose. There Are Now 19 Biosimilar Competitors. Here’s What That Means for Patients. The KRESLADI Trial Data That Just Earned the First Gene Therapy Approval for LAD-I Enhertu Is Now FDA-Approved for HER2-Positive Early Breast Cancer Before and After Surgery. Here Is What the DESTINY-Breast11 and DESTINY-Breast05 Data Shows. High Blood Pressure That Won’t Budge on Multiple Medications Just Got Its First New Drug Class in Decades. Here Is What Baxfendy Is and What the BaxHTN Data Shows. Fasenra Just Got a Third Approved Indication. Here Is What Hypereosinophilic Syndrome Is and What the NATRON Trial Data Actually Shows. GLP-1 Drugs and Suicidal Thoughts: The FDA Reviewed 107,910 Patients and 2.2 Million Real-World Users. What It’s Now Asking Drug Makers to Remove. Your Asthma Is Still Not Controlled on Two Inhalers. The FDA Just Approved a Third Drug You Can Add Without Adding a Second Device. Ovarian Cancer Has Resisted Almost Every Drug Thrown at It in the Platinum-Resistant Setting. Lifyorli™ Just Changed That by Targeting Cortisol. AVLAYAH Approved: For Hunter Syndrome Families, This FDA Decision Hits Different That Itch That Won’t Quit: Inside the FDA Approval That PBC Patients Have Been Waiting For The First Oral IL-23 Receptor Blocker for Psoriasis Is FDA-Approved. Here Is What the ICONIC Trial Data Actually Shows. The FDA Rejected Replimune’s RP1 for Melanoma. Here Is Exactly Why, and What Has to Happen Next. The FDA Just Added a New Warning to All Carbidopa/Levodopa Parkinson’s Medications. Here Is What It Says and Why It Matters. Once-Weekly Navepegritide Is Now FDA-Approved for Children With Achondroplasia. Here Is What the APPROACH Trial Data Actually Shows. Cancer Outcomes Are Worse for LGBTQ+ Patients. The Research Infrastructure to Address That Is Just Getting Started. Two Pills Instead of Three, No Tenofovir, No INSTI. The FDA Just Approved a New Way to Maintain HIV Suppression. The FDA Just Removed Boxed Warnings From Six Hormone Therapy Products. Here Is What Changed, What Stayed, and Why It Matters. The FDA Just Removed the Age Limit on Needle-Free Epinephrine. Here Is What Families and Caregivers Need to Know. A Fatal Childhood Disease Has No Treatment. A Gene Therapy with Eight Years of Data Is Now Under FDA Review. Here Is What the Evidence Shows. Younger Endometrial Cancer Survivors Face Years of Unnecessary Suffering. New Evidence Says One Treatment Has Been Wrongly Withheld. One in Three Women with Premature Ovarian Insufficiency Gets the Hormone Therapy They Need. Here Is Why That Number Should Be Much Higher. Tavneos (Avacopan) and Serious Liver Injury: What Patients and Clinicians Need to Know, Including What the FDA Isn’t Saying Publicly The First BCL-2 Inhibitor Specifically Approved for Mantle Cell Lymphoma Just Received FDA Clearance. Here Is What the Data Shows. The FDA Approved Foundayo. It Also Required These Post-Marketing Studies. Here Is What That Means and Why It Is Normal Practice. An Experimental Immunotherapy Just Got FDA Orphan Drug Status for Sarcoma. Here Is What the EFTISARC-NEO Trial Data Actually Shows. Generic Dapagliflozin Is Here. For 40 Million Americans With Type 2 Diabetes, That’s a Big Deal. About Health Evidence Digest IZERVAY Can Now Be Used Beyond 12 Months. The Two-Year GATHER2 Data That Earned That Label Change and What It Means for Patients with Geographic Atrophy. The First Gene Therapy for Deafness Is Here and It’s Free. Here’s What That Actually Means. The FDA Just Fast-Tracked Three Psychedelic Drug Programs. Here’s What the Clinical Evidence Behind Them Actually Shows. A New Kind of Botox That Wears Off in Weeks Just Hit a Regulatory Snag. Here’s What That Means and What Patients Considering Neurotoxins Actually Need to Know. Sarclisa Is Already Approved for Multiple Myeloma. Now Sanofi Wants to Deliver It Without the IV. The Phase 3 Evidence Behind That Ambition. A New Device for Detecting Uterine Cancer in the Doctor’s Office Just Received FDA Clearance. Here Is Who Should Know About It. A New AI Tool Can Help Predict Which Breast Cancer Patients Can Skip Chemotherapy. The FDA Just Cleared It. The FDA Just Published a Safety Roadmap for Gene Editing Therapies. Here Is What the NGS Guidance Actually Covers and Why It Matters. Wegovy HD: The FDA Just Approved a Semaglutide Dose Three Times Stronger Than Before. Here’s What the Data Actually Shows. The FDA Just Launched Real-Time Clinical Trials. Here Is What That Means, Why It Matters, and What Could Go Wrong. Hands. Grip. Independence. What the FDA’s Clearance of the ExaStim® System Actually Means for Spinal Cord Injury Rehab.